Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 11Blastic Plasmacytoid Dendritic Cell Neoplasm 6Leukemia, Myelomonocytic, Chronic 3Recurrence 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Hematologic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 78fludarabine phosphate 77Azacitidine 76Peripheral Blood Stem Cell Transplantation 63Busulfan 53Mycophenolic Acid 51Whole-Body Irradiation 50Tacrolimus 48Cytarabine 43Cyclosporine 43Methotrexate 37Decitabine 36Filgrastim 32Antilymphocyte Serum 30venetoclax 27Radiotherapy 25Melphalan 23fludarabine 22Etoposide 18Methylprednisolone 17Biopsy 15Cyclosporins 14Specimen Handling 13Injections 13Granulocyte Colony-Stimulating Factor 13Flow Cytometry 13Cord Blood Stem Cell Transplantation 13decitabine and cedazuridine drug combination 12Idarubicin 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × tagraxofusp × Clear all
NCT05038592 2026-04-14

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
64 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT05233618 2025-05-28

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

University of Virginia

Phase 1 Recruiting
44 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT02268253 2025-01-06

Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

Stemline Therapeutics, Inc.

Phase 1/2 Completed
82 enrolled 15 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡